about
Role of active metabolites in the use of opioidsA cortical source localization analysis of resting EEG data after remifentanil infusion.Patient-related barriers to cancer pain management: a systematic exploratory review.Differences between opioids: pharmacological, experimental, clinical and economical perspectivesRelationships among morphine metabolism, pain and side effects during long-term treatment: an update.Exploratory survey study of long-term users of nicotine replacement therapy in Danish consumersBlood-brain distribution of morphine-6-glucuronide in sheep.Morphine- and buprenorphine-induced analgesia and antihyperalgesia in a human inflammatory pain model: a double-blind, randomized, placebo-controlled, five-arm crossover studyTranslational pain research: evaluating analgesic effect in experimental visceral pain models.Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.A review of morphine and morphine-6-glucuronide's pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain.Cortical and spinal assessment - a comparative study using encephalography and the nociceptive withdrawal reflex.Barriers to cancer pain management in Danish and Lithuanian patients treated in pain and palliative care units.Switching from high doses of pure μ-opioid agonists to transdermal buprenorphine in patients with cancer: a feasibility study.Psychological and behavioural predictors of pain management outcomes in patients with cancer.Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery.Pharmacokinetics, efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study.Repeated Time-to-event Analysis of Consecutive Analgesic Events in Postoperative Pain.Altered cortical causality after remifentanil administration in healthy volunteers: a novel approach for pharmaco-EEG.Population pharmacokinetics of morphine and morphine-6-glucuronide following rectal administration--a dose escalation study.Renal function and symptoms/adverse effects in opioid-treated patients with cancer.Differential effect of opioids in patients with chronic pancreatitis: an experimental pain study.Stereoselective pharmacokinetics of methadone in chronic pain patients.Pharmacokinetic/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models.A pharmacokinetic and pharmacodynamic study of oral oxycodone in a human experimental pain model of hyperalgesia.Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group.Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists.Danish pain specialists' rationales behind the choice of fentanyl transdermal patches and oral transmucosal systems--a delphi study.The impact of an electronic monitoring and reminder device on patient compliance with antihypertensive therapy: a randomized controlled trial.Changing M3G/M6G ratios and pharmacodynamics in a cancer patient during long-term morphine treatment.Pain, sedation and morphine metabolism in cancer patients during long-term treatment with sustained-release morphine.A physiologically-based recirculatory meta-model for nasal fentanyl in man.Symptoms and side effects in chronic non-cancer pain: patient report vs. systematic assessment.Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug.Quality of life and symptoms in patients with malignant diseases admitted to a comprehensive cancer centre.Pharmacodynamic modelling of placebo and buprenorphine effects on event-related potentials in experimental pain.Pharmacokinetic-pharmacodynamic relationships of cognitive and psychomotor effects of intravenous buprenorphine infusion in human volunteers.Pharmacokinetic-pharmacodynamic modeling of morphine and oxycodone concentrations and analgesic effect in a multimodal experimental pain model.Patients' evaluation of shape, size and colour of solid dosage forms.
P50
Q28298981-A414F686-A24C-4AD4-92A7-2AF6EDDC100FQ30852102-F76093E0-1183-49F6-AF05-04A9A32FDE0EQ33368816-EAD46A4F-6083-4AEB-A4CD-E1DF61818856Q34272502-1AD18870-7588-41AA-8BED-B4BCF7D0BA8FQ35059001-3F1F3B43-26E7-4CE5-A705-2CD247EAC15DQ35910691-C2053D31-8BDC-4CAE-AC95-FD6734F4E9F8Q36054363-44875FA1-C415-4F1B-94E3-FEFAB3C19681Q36564008-569E7D47-D8EB-4290-B0B5-8FA53AC3142FQ37365359-3B90C2E8-66B8-47AC-AF49-965B3E086E09Q38247246-84511EE7-80F8-4C2F-A599-9027E231B238Q38415013-B5C2DC72-5699-4CD4-8152-1A099836E237Q39090587-93CB948E-DEC5-4AD7-88BE-FCC4A1EEC8FFQ39210657-90D8F154-BDF2-44DE-8B6E-8268C95A86B7Q39215359-94E65532-B21C-44F4-BEDD-43F030F4AF40Q39285697-17FCAE67-3CB5-4C15-9633-F05BC50D347FQ39315334-8692E2DC-7F1C-4FEC-BB60-3DB5EF324B8DQ39321110-0BE613CC-0A5D-42EF-A379-BDD5FA86B2F9Q40398946-72857F58-334E-473C-8F38-490ACBC46CB3Q41605933-EB6E2E91-5451-494F-84F7-C5E603F80D3BQ41716246-60D327A8-76D0-4766-BCAA-7C3DE2A23C25Q41760447-1C108944-755F-4E07-AA37-43F286175351Q42167015-EE6C3DF0-3125-4B4D-9AB9-3F4098100140Q42635479-D09610EB-F67B-41CF-8C03-F95D618D687DQ42783945-E19B02D5-55C4-490E-BB25-16832A5D685BQ42875497-59745FA5-D38F-497C-BFC8-7735F0C3B9B7Q43062741-6175AF2D-610F-4941-A871-35FC92C2CCC5Q43070644-2174B89A-A141-48BB-9CE1-628BE2E60F47Q43269058-0B4D61ED-0706-4D71-A5AF-D029446C84B4Q43273331-73930E8D-6EC7-4C01-AECA-A90FD57B21A1Q43886119-D300C929-5768-4ECB-A5B6-F41A941B4213Q43968416-06D8E988-A89A-4034-8FC0-5258C64317FCQ44317087-1F58AC46-608C-4A53-B0CC-DF475A254F7EQ44467270-5729A469-AB9B-4189-AE1A-42879603498AQ44862502-58D24F55-198B-41E9-A594-06D3731C64A9Q45284882-C1F78418-FA06-4C6C-BEEC-8D93968062EDQ45514142-556F0BD4-C636-4977-9709-FA2A014B5F31Q45941206-2A3FF331-6757-40A5-AE6E-1C0D2FD45799Q46504210-C604095D-EE91-4D92-9D7F-F3E7A3D82DF0Q46623382-FE349205-730A-45F0-8D18-66B042091BC7Q47198281-753C5551-ED4C-4BFE-80B7-1F37A911DB40
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Lona Louring Christrup
@ast
Lona Louring Christrup
@en
Lona Louring Christrup
@es
Lona Louring Christrup
@sl
type
label
Lona Louring Christrup
@ast
Lona Louring Christrup
@en
Lona Louring Christrup
@es
Lona Louring Christrup
@sl
prefLabel
Lona Louring Christrup
@ast
Lona Louring Christrup
@en
Lona Louring Christrup
@es
Lona Louring Christrup
@sl
P106
P1153
7004286303
P21
P31
P3835
lona-christrup
P496
0000-0002-4128-7373